Record $338 billion savings in 2020 from copy meds in USA

27 September 2021

The USA’s Association for Accessible Medicines (AAM), the trade body for generic and biosimilar manufacturers, has released the top-line findings from its forthcoming 2021 Generic Drug and Biosimilars Savings in the US report highlighting the value of generic and biosimilar drugs.

According to the analysis, the US health care system saved $338 billion in 2020 through the use of Food and Drug Administration-approved generic and biosimilar drugs.

90% of the prescriptions filled in the USA in 2020 were filled by generic drugs, but those prescriptions accounted for only 18% of the country’s spending on prescription drugs.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK